Targeted therapies in advanced differentiated thyroid cancer

Raquel M. Carneiro*, Benedito A. Carneiro, Mark Agulnik, Peter A. Kopp, Francis J. Giles

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

47 Scopus citations


Differentiated thyroid cancer is the most common endocrine malignancy, and its incidence has been rising rapidly over the past 10. years. Although most patients with this disease have an excellent prognosis, a subset develops a more aggressive disease phenotype refractory to conventional therapies. Until recently, there was no effective therapy for these patients. With increasing knowledge of the molecular pathogenesis of thyroid cancer, novel targeted therapies are being developed for this group of patients. Sorafenib and lenvatinib, small-molecule multikinase inhibitors, were approved for the treatment of progressive, symptomatic, radioactive iodine refractory, advanced differentiated thyroid cancer in 2013 and 2015, respectively. This represents a major innovation in the therapy of patients with advanced thyroid cancer. However, these therapies still have many limitations and further research needs to be pursued with the ultimate goal of providing safe and effective personalized therapy for patients with advanced thyroid cancer.

Original languageEnglish (US)
Pages (from-to)690-698
Number of pages9
JournalCancer Treatment Reviews
Issue number8
StatePublished - Sep 1 2015


  • Differentiated thyroid cancer
  • Follicular thyroid carcinoma
  • Targeted therapy
  • Thyroid cancer
  • Tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging


Dive into the research topics of 'Targeted therapies in advanced differentiated thyroid cancer'. Together they form a unique fingerprint.

Cite this